Pulse Biosciences stock reaches 164 patient study target

Published on 10/08/2026 at 00:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulse Biosciences stock was at USD 50.66 on Nasdaq on October 7, 2026, up 0.31 percent. The company enrolled 164 evaluable patients.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences stock (ISIN US74587B1017) was trading at USD 50.66 on Nasdaq on October 7, 2026, at 9:46 a.m. EDT, up 0.31 percent from the USD 50.50 prior close. The company then reached a 164-patient enrollment target in its pivotal atrial fibrillation study, giving the stock a concrete clinical milestone to assess.

Enrollment reaches 164 patients

Business Wire reported on October 7, 2026, that Pulse Biosciences enrolled 164 evaluable participants across 15 clinical sites in the NANOPULSE-AF IDE pivotal study.

The study is testing the nPulse Cardiac Catheter System in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation. Enrollment finished three months ahead of the original nine-month timeline, while the primary endpoints will be assessed six and 12 months after ablation, according to Business Wire.

Analysts see a divided valuation

The analyst backdrop is more bullish than the latest trading level. According to MarketBeat on October 6, 2026, seven analysts gave the stock a Moderate Buy consensus, with an average 12-month price target of USD 50.20 and a highest target of USD 70.00.

Canaccord also raised its target to USD 58.00 from USD 43.00 while maintaining a Buy rating, as Investing.com reported on October 6, 2026. That target is USD 7.34 above the October 7 trading price, while the consensus average is USD 0.46 below it, showing that the published estimates are not aligned.

Clinical data set the next checkpoint

For investors, enrollment is only the first measurable step because the study still depends on six-month and 12-month safety and effectiveness outcomes. Pulse Biosciences said it expects to present pivotal data at a future medical society conference, linking the enrollment milestone to a later evidence checkpoint rather than an immediate commercial launch.

The company develops bioelectric medicine technologies based on nanosecond electrical pulses. Its CellFX System is the initial commercial product, while the nPulse platform is being developed for atrial fibrillation and other medical applications, according to the company's investor-relations profile at Pulse Biosciences.

Pulse Biosciences stock stays near its yearly high

Pulse Biosciences stock was trading at USD 50.66 on Nasdaq on October 7, 2026, at 9:46 a.m. EDT, compared with a 52-week range of USD 12.56 to USD 58.90. The market capitalization was USD 3.6 billion as of October 6, 2026.